ライフサイエンスコーパス: ER-beta

1 ER-beta can play an important role in CRC development an

2 ER-beta mRNA was significantly up-regulated in the tamox

3 ER-beta only modestly affected FR-alpha promoter activit

4 ER-beta variants were also detected.

5 ER-beta/PV double-labeled cells are also observed within

6 ER-beta/PV double-labeled cells represent 23.3% +/- 1.6%

7 of these studies have demonstrated that (1) ER beta mRNA is translated into immunoreactive protein t

8 ve protein throughout the rat brain, and (2) ER beta resides in the cell nucleus.

9 these studies indicate that ligand-activated ER-beta is a potential therapeutic target to combat obes

10 Almost all ER-beta-immunoreactive cells within the subiculum, a maj

11 .8% (intact) and 94.5% +/- 1.4% (ovx) of all ER-beta-immunoreactive cells coexpress parvalbumin, and

12 ive brain area reported to express ER alpha, ER beta, and PR.

13 a and PR, and PC-3 cells exhibited ER-alpha, ER-beta, and pS2 mRNA.

14 the region-specific expression of ER-alpha, ER-beta, or both may be important in determining the phy

15 ition of the four genes coding for ER-alpha, ER-beta, OT, and the OT receptor.

16 fter the raloxifene treatment, PC3 (ER-alpha/ER-beta+) and DU145 (ER-beta+ only) cells were selected

17 vasopressin-immunoreactive neurons were also ER-beta positive in the PVN (66.14% +/- 2.47%) and SON (

18 a the estrogen receptor (ER)-alpha, although ER-beta and G protein-coupled estrogen receptor 1 also m

19 An ER-beta-selective ligand increased markers of tricarboxy

20 agonist [propylpyrazoletriol (PPT)], and an ER-beta agonist [WAY-200070 (WAY)] with TNF-alpha or pla

21 (i) ER-beta1 is the obligatory partner of an ER-beta dimer, whereas the other isoforms function as va

22 versed by cotreatment of DU145 cells with an ER-beta antisense oligonucleotide, hence lending additio

23 gues can activate ER alpha(Glu353-->Ala) and ER beta(Glu305-->Ala) with very large selectivites, demo

24 , whereas CAV3 is necessary for ER alpha and ER beta activation of mGluR2/3.

25 ER alpha and ER beta agonists PPT and DPN inhibited and 4-OHT increas

26 Both ER alpha and ER beta contribute to E2-mediated EPC activation and tis

27 elped to delineate the roles of ER alpha and ER beta in modulating transcription of genes containing

28 discriminate between different ER alpha and ER beta ligand complexes suggests that the biological ef

29 , in weanling rats sex affected ER alpha and ER beta neuronal densities in brainstem regions associat

30 factor requirements, domains of ER alpha and ER beta sufficient for forskolin/IBMX activation, and th

31 n, we compared the abilities of ER alpha and ER beta to activate transcription and induce distortion

32 The different abilities of ER alpha and ER beta to induce change in DNA structure could foster o

33 istinct mechanisms to stimulate ER alpha and ER beta transcriptional activity.

34 ivators stimulated cAMP-induced ER alpha and ER beta transcriptional activity.

35 , those tumors that coexpressed ER alpha and ER beta were node positive (P = 0.02; Fisher's exact tes

36 sion of the estrogen receptors (ER alpha and ER beta) on the globoid cells, activated astrocytes and

37 ng the biological roles of both ER alpha and ER beta, and they might form the basis for the developme

38 estrogen receptor (ER) subtype, ER alpha and ER beta, in the injured brain.

39 ains (E domains) of human/mouse ER alpha and ER beta, progesterone receptors A and B, and the androge

40 antitate areas and densities of ER alpha and ER beta-positive neurons within medullary regions associ

41 nscriptional activities of both ER alpha and ER beta.

42 on through the two ER subtypes, ER alpha and ER beta.

43 at ADA3 directly interacts with ER alpha and ER beta.

44 with estrogen receptor alpha (ER alpha) and ER beta bound to a variety of ligands.

45 xpression of ADA3 enhances the ER alpha- and ER beta-mediated sequence-specific transactivation.

46 uding the classical nuclear ERs (ERalpha and ER beta ), that typically regulate gene expression, and

47 we used ER alpha-knockout (ER alpha KO) and ER beta-knockout (ER beta KO) mice in an animal model of

48 which were developed as nuclear ER-alpha and ER-beta agonists/antagonists, have previously been impli

49 inhibitory activities and high ER-alpha and ER-beta binding affinities of several of the resulting a

50 R and Western blot analysis for ER-alpha and ER-beta demonstrated that all three cell lines express E

51 henotype in mice that lack both ER-alpha and ER-beta genes (alphabetaERKO).

52 to investigate the presence of ER-alpha and ER-beta in normal and malignant colon tissue.

53 tudies revealed the presence of ER-alpha and ER-beta mRNA throughout the rostral-caudal extent of the

54 ation about the distribution of ER-alpha and ER-beta mRNAs in the rat CNS.

55 l increased the density of both ER-alpha and ER-beta protein clusters along dendrites.

56 ice had decreased expression of ER-alpha and ER-beta subtypes and ER transcriptional activity was als

57 pression of estrogen receptor (ER)-alpha and ER-beta subtypes in GS-prone and GS-resistant glomeruli

58 and BPH-1 cells expressed both ER-alpha and ER-beta transcripts and no PR nor pS2 mRNA in PrEC and o

59 Expression levels of ER-alpha and ER-beta transcripts were related to those of two estroge

60 ncreases in estrogen receptors (ER-alpha and ER-beta) and a decrease in progesterone receptor levels,

61 X is functionally distinct from ER-alpha and ER-beta, and that, like ER-alpha, it is re-expressed in

62 in the ligand-binding domain of ER-alpha and ER-beta, we were not surprised to find that SP500263 bin

63 ural estrogen genistein at both ER-alpha and ER-beta, whereas AIB1 had no effect on either the potenc

64 GGTCAnnnTGACC, which bind both ER-alpha and ER-beta.

65 xpress both estrogen receptor (ER)-alpha and ER-beta.

66 Estrogen receptor-alpha (ER-alpha) and ER-beta exhibit fine differences in their distributions

67 both estrogen receptor-alpha (ER-alpha) and ER-beta in ovarian, breast and endometrial cancer cell l

68 ssociated with reduced risk of ER-alpha- and ER-beta-expressing NSCLC.

69 ther with the inability of the ER-alpha- and ER-beta-selective ligands to elicit ERK phosphorylation,

70 17-diol (ICI 182,780)] and the ER-alpha- and ER-beta-specific agonists [1,3,5-tris(4-hydroxyphenyl)-4

71 abolish receptor binding, and ER-alpha- and ER-beta-specific antibodies interact with complexes form

72 n functions signaled through hER-alpha66 and ER-beta; it also transduces membrane-initiated estrogen-

73 nd the number of cortical GABA, ER-beta, and ER-beta/GABA double-labeled neurons was examined.

74 utions of ER-alpha immunoreactivity (ir) and ER-beta ir were nonoverlapping in the PVN and SON.

75 Expression of FOS-IR in MNCs with attenuated ER-beta-IR, and the absence of FOS-IR in parvocellular n

76 Because ER-beta is thought to function as an inhibitor of prosta

77 ta expression was selective for MNCs because ER-beta-IR remained unaltered in PVN parvocellular neuro

78 strogen receptors alpha (ER alpha) and beta (ER beta) in EPC biology are largely unknown.

79 lar receptors, alpha (ER alpha) and/or beta (ER beta), and the progestin receptor (PR).

80 The discovery of estrogen receptor beta (ER beta) and subsequent localization of its mRNA in the

81 nation therapy of an estrogen receptor beta (ER beta) inhibitor with a sTNF/TNFR1 or general p38MAPK

82 or alpha (ER alpha), estrogen receptor beta (ER beta), progesterone receptor (PR), and androgen recep

83 etermine the role of estrogen receptor beta (ER-beta) and its ligands on adipose biology.

84 Estrogen receptor beta (ER-beta) and its selective ligand reprogrammed preadipoc

85 Estrogen receptor beta (ER-beta) regulates diverse physiological functions in th

86 alpha (ER-alpha) and estrogen receptor beta (ER-beta), and antagonize the activity of beta-estradiol

87 nd binding domain of estrogen receptor beta (ER-beta).

88 cently characterized estrogen receptor-beta (ER-beta) has not been examined in vivo.

89 at the activation of estrogen receptor-beta (ER-beta) plays an important cardioprotective role agains

90 s proliferation via oestrogen receptor-beta (ER-beta), the catecholoestradiols mediate P-UAEC prolife

91 its specificity for estrogen receptor-beta (ER-beta), was used to immunolocalize the receptor in his

92 lpha (ER-alpha), and estrogen receptor-beta (ER-beta), we found only sparse colocalization between ER

93 ctivation of estrogen receptor subtype beta (ER-beta).

94 Comparisons were made between ER-beta, estrogen receptor-alpha (ER-alpha), and androge

95 dzein and genistein (compounds known to bind ER-beta) were performed to serve as positive controls.

96 nteracting with ER alpha, ERAP140 also binds ER beta, TR beta, PPAR gamma, and RAR alpha.

97 P-dependent activation of gene expression by ER beta but not ER alpha, indicating that the former sub

98 The inhibition of anoikis by ER-beta-catenin can be abolished by a mitogen-activated

99 and anticancer effects that are mediated by ER-beta.

100 780 blocks activation by ER-alpha but not by ER-beta.

101 ditional support to a central role played by ER-beta in mediating growth-inhibitory action of antiest

102 We hypothesize that estrogen protects by ER-beta activation, which leads to S-nitrosylation (SNO)

103 This phenotype was partially reversed by ER-beta-selective ligand.

104 ER-beta-specific antibodies to characterize ER-beta protein expression in breast cancer cell lines a

105 ptor (ER) alpha and the more recently cloned ER-beta.

106 ent of both ER-alpha and the recently cloned ER-beta.

107 entage of oxytocin (OXY) neurons coexpressed ER-beta in the PVN (84.39% +/- 2.99%), there was very li

108 n erythroleukemia (HEL) cells also contained ER beta and AR transcripts.

109 ling and discovered that axons from cortical ER-beta-expressing inhibitory neurons terminate on BDNF-

110 Given the recent finding that cortical ER-beta is almost exclusively localized to parvalbumin-i

111 he RNA expression studies, we have developed ER-beta-specific antibodies to characterize ER-beta prot

112 Regardless of these differences, ER beta-mediated regulation of GST-Pi and GCSh point tow

113 alpha agonist), or diarylpropionitrile (DPN, ER-beta agonist) before allergen challenge to determine

114 reatment, PC3 (ER-alpha/ER-beta+) and DU145 (ER-beta+ only) cells were selected to further characteri

115 (ER) until the recent cloning of a novel ER (ER-beta).

116 cloning of a second estrogen receptor (ER), ER beta, has prompted a reevaluation of the role of ERs

117 Based on our recent finding of anti-estrogen/ER-beta-mediated growth inhibition of prostate cancer ce

118 cord, and pineal gland contained exclusively ER-beta mRNA.

119 s been demonstrated that LNCaP cells express ER-beta but not ER-alpha and that tamoxifene induces apo

120 monstrated that all three cell lines express ER-beta, whereas only PC3 and PC3M cells were positive f

121 oximately 7.5% of oxytocin (OT) MNCs express ER-beta.

122 pin-releasing hormone neurons also expressed ER-beta ir in the PVN (12.57% +/- 1.99%), but there was

123 prostate cancer cell lines, LNCaP expressed ER-beta mRNA along with transcripts of PR and pS2, DU145

124 howed variation in the size of the expressed ER-beta protein.

125 , with 22% of samples exclusively expressing ER beta; this was not observed in any of the breast tumo

126 urons with the highest percentage expressing ER-beta was found to be prolactin (PRL) immunoreactive i

127 tients with 5-FU-resistant tumors expressing ER-beta protein.

128 tase], "estrogen metabolism/ER-beta factor" (ER-beta, peroxisome proliferator-activated receptor-gamm

129 l human CD34(+) stem cells contained RNA for ER beta and AR, which increased with cell differentiatio

130 and GCSh point towards an important role for ER beta in cellular protection against oxidative stress.

131 contained cells that were immunostained for ER-beta.

132 sections were double- or triple-labeled for ER-beta, GABAergic, and BDNF immunomarkers.

133 ber of perirhinal neurons double-labeled for ER-beta/GABA was reduced by 28% (P<0.01 compared to vehi

134 Numerous MNCs were positive for ER-beta in control animals, but they were virtually devo

135 e results lend further support to a role for ER-beta as a poor prognostic factor in breast cancer.

136 These data highlight a new role for ER-beta in adipose biology and its potential to be a saf

137 elease, this suggests an inhibitory role for ER-beta in MNCs.

138 with beta-LGNDs demonstrated selectivity for ER-beta over ER-alpha.

139 anslationally modified form of the long-form ER-beta, which has a predicted size of 59 kd based on po

140 Furthermore, ER-beta and BDNF do not colocalize in any brain region.

141 replacement and the number of cortical GABA, ER-beta, and ER-beta/GABA double-labeled neurons was exa

142 In general, ER beta-positive neurons in the brainstem regions examin

143 Silencing of hippocampal ER-beta attenuated E2-mediated ischemic protection sugge

144 ory of both ERs and discuss the implications ER beta has to patients with breast cancer.

145 In contrast sex differences in ER beta were found in fewer nuclei, but in those higher

146 or propyl pyrazole triol in wild-type and in ER-beta-/- mice.

147 The osmotically induced decrease in ER-beta expression was selective for MNCs because ER-bet

148 ochemistry demonstrated that the decrease in ER-beta mRNA was translated into depletion of receptor p

149 transcription-PCR revealed no difference in ER-beta mRNA levels between normal and malignant colon t

150 cardioprotective effect of DPN was found in ER-beta-knockout mice, indicating that the DPN-induced c

151 ivo findings that methylation is involved in ER-beta silencing.

152 fects of ER-beta ligand were not observed in ER-beta-knockout mice.

153 ia d-d-arginine VP and liquid diet increased ER-beta mRNA expression in MNCs (p < 0.05).

154 The AD-like effect of estradiol involved ER beta and G-protein coupled receptor 30, whereas its b

155 knockout (ER alpha KO) and ER beta-knockout (ER beta KO) mice in an animal model of stroke.

156 We ovariectomized ER alpha KO, ER beta KO, and the respective wild-type mice and implan

157 adiol differ dramatically among ER alpha KO, ER beta KO, and wild-type mice.

158 sistent with the 530-amino acid, full-length ER-beta sequence.

159 lines (LNCaP and DU145), that express little ER-beta mRNA, with a demethylating agent increased level

160 VN (84.39% +/- 2.99%), there was very little ER-beta/OXY colocalization in the SON.

161 ting the first 18 amino acids of the longest ER-beta open reading frame reported to date, and polyclo

162 ndometrium (4.9) mainly as a result of lower ER-beta expression in the former.

163 profiling; however, the estrogen metabolism/ER-beta factor seemed to be distinctive.

164 lin D1, and aromatase], "estrogen metabolism/ER-beta factor" (ER-beta, peroxisome proliferator-activa

165 , and in contrast to the estrogen metabolism/ER-beta factor, higher current body mass index among pre

166 d developmentally regulated, and neocortical ER-beta, which is intranuclear and expressed throughout

167 The present study used a new ER beta-specific polyclonal antiserum (Z8P) and immunocy

168 the PVN (12.57% +/- 1.99%), but there was no ER-beta colocalization with TRH.

169 he developing brain, is neither ER-alpha nor ER-beta but a novel, plasma membrane-associated, putativ

170 estrogen receptor-alpha (ER alpha), but not ER beta, inhibited estrogen-stimulated telomerase functi

171 will require antagonism of ER alpha but not ER beta.

172 pressed estrogen receptor (ER)alpha, but not ER-beta protein levels, and abrogated downstream estroge

173 A and protein expression of ER-alpha but not ER-beta were suppressed by resveratrol in Ishikawa cells

174 or an estrogen receptor (ER)-alpha (but not ER-beta) agonist into the dorsal hippocampus rapidly imp

175 s were intact in male mice lacking the novel ER-beta gene.

176 ution of the classical (ER-alpha) and novel (ER-beta) forms of ER mRNA-expressing neurons in the cent

177 ted with cytoplasmic ER-alpha and/or nuclear ER-beta expression-defined NSCLC in postmenopausal women

178 njury is totally preserved in the absence of ER beta.

179 try (ICC) to investigate the distribution of ER beta in the rat CNS.

180 In normal breast tissue, expression of ER beta predominated, with 22% of samples exclusively ex

181 g through the AP1 element, overexpression of ER beta in tumors expressing both ER subtypes may explai

182 ern immunoblotting confirmed the presence of ER beta and AR in platelets.

183 vity by hPMC2 is enhanced in the presence of ER beta.

184 osphorylation of the corresponding region of ER beta, and this correlates with the lack of forskolin/

185 A critical step in understanding the role of ER beta is demonstrating that the mRNA is translated int

186 Targeting of ER beta or G-protein coupled receptor 30 might reveal a

187 avourable disease outcome, the usefulness of ER beta as a clinical prognostic marker remains to be de

188 used to determine the mechanism of action of ER-beta and its ligands.

189 re protects hearts largely via activation of ER-beta and nitric oxide/SNO signaling.

190 The activation of ER-beta by DPN treatment leads to increased protein SNO

191 Activation of ER-beta diminishes ECM deposition via suppressing the NF

192 The activation of ER-beta-catenin signaling rescues RK3E cells from anoiki

193 oprotection occurs through the activation of ER-beta.

194 for studying ER-beta signaling and design of ER-beta-based therapies.

195 l animals, but they were virtually devoid of ER-beta-immunoreactivity (IR) in hyper-osmotic animals.

196 on is associated with a marked diminution of ER-beta protein expression, possibly through a posttrans

197 tions requiring the ligand binding domain of ER-beta and through abrogation of the ability of PGC-1 t

198 We evaluated the pharmacological effect of ER-beta-selective ligands (beta-LGNDs) in animal models

199 The antiobesity effects of ER-beta ligand were not observed in ER-beta-knockout mic

200 Expression of ER-beta in metastases may have been influenced by the lo

201 Thus, the expression of ER-beta mRNA correlated inversely with changes in plasma

202 se relationship exists between the extent of ER-beta CGI methylation and receptor expression in norma

203 The importance of ER-beta in tamoxifen resistance was validated using tamo

204 CGIs, led to transcriptional inactivation of ER-beta.

205 hat antiestrogens antagonize E2 induction of ER-beta mRNA.

206 ecause the prostate contains a high level of ER-beta, the present study investigated the effect of ra

207 Because the prostate contains high levels of ER-beta, the present study investigated the effect of ra

208 arcinogenesis was characterized by a loss of ER-beta expression at the protein and transcript levels

209 promoter CGI, which correlated with loss of ER-beta expression, was detected in microdissected sampl

210 nant colon tissue showed a selective loss of ER-beta protein expression when compared to normal colon

211 post-ischemic hippocampal injury by means of ER-beta activation.

212 s of PR and pS2, DU145 expressed messages of ER-beta and PR, and PC-3 cells exhibited ER-alpha, ER-be

213 Thus, osmotic modulation of ER-beta expression in MNCs may augment or attenuate an i

214 - 3.1% (intact) and 26.0% +/- 5.2 % (ovx) of ER-beta-immunoreactive cells coexpress PV.

215 try to further characterize the phenotype of ER-beta-bearing cells by double labeling for the GABAerg

216 However, the potential of ER-beta-selective ligands to offset obesity is not clear

217 state cancer cells in vitro, the presence of ER-beta in metastatic cells may have important implicati

218 We find that a large proportion of ER-beta-immunoreactive cells within the cortex, amygdala

219 ranslated exon 0N and the promoter region of ER-beta.

220 for neuronal activation in the regulation of ER-beta expression in MNCs.

221 first evidence that epigenetic regulation of ER-beta is a reversible and tumor stage-specific process

222 We examined the osmotic regulation of ER-beta mRNA expression in MNCs using quantitative in si

223 of estrogen receptor (ER)-alpha and those of ER-beta were expressed in our normal PrEC primary cultur

224 Interestingly, only transcripts of ER-beta, but not those of ER-alpha, were found in our pr

225 tection assay a mRNA coding for a variant of ER-beta that is coexpressed with wild-type ER-beta in th

226 activity on ER alpha while being inactive on ER beta.

227 t binds to both receptors, but enhances only ER beta interaction with SRC1 and SRC3 while exhibiting

228 contrast, in DU145 cells, which express only ER-beta, antiestrogens, but not estrogens, are growth in

229 2-mediated responses were due to ER alpha or ER beta signaling, ER alpha-knockout (alphaERKO) or ERbe

230 for one of the two ER subtypes, ER alpha or ER beta.

231 ense riboprobes complimentary to ER-alpha or ER-beta mRNA, stringently washed, and opposed to emulsio

232 In cells containing either ER-alpha or ER-beta, the 3'-element behaves as a traditional enhance

233 es were associated with nuclear ER-alpha- or ER-beta-negative NSCLC.

234 sk of NSCLC characterized as ER-alpha and/or ER-beta positive.

235 estrogen receptor-alpha (ER-alpha, Esr1) or ER-beta (Esr2) increased ILC2-mediated airway inflammati

236 expression plasmid pCI-ER alpha, but not pCI-ER beta, aromatase activity was elevated by 17beta-estra

237 cates the involvement of another ER, perhaps ER beta.

238 Additionally, periodic ER-beta agonist treatments every 48 hr improved post-isc

239 gene for a likely gene duplication product, ER-beta, did not have these effects.

240 In normal prostate, ER-beta immunostaining was predominately localized in th

241 Recently, ER-beta (ERbeta) mRNA and protein were shown to be expre

242 cently discovered estrogen-binding receptor, ER beta.

243 abundant cortical nuclear estrogen receptor, ER-beta, is present in GABAergic neurons, prompting us t

244 FOS-IR in parvocellular neurons that retain ER-beta-IR suggest a role for neuronal activation in the

245 Shorter ER-beta isoforms were detected in the ER-alpha-negative

246 viously unrecognized directions for studying ER-beta signaling and design of ER-beta-based therapies.

247 e after trauma-hemorrhage and female 129 Sve ER-beta-/- transgenic mice and ovariectomized wild-type

248 s containing the consensus ERE sequence than ER beta.

249 more potent activator of transcription than ER beta in bone, uterine, and mammary cells.

250 induced higher levels of transcription than ER beta in the presence of 17 beta-estradiol.

251 d the major groove of the DNA helix but that ER beta failed to induce a directed DNA bend.

252 C/ in situ hybridization study revealed that ER beta mRNA and immunoreactivity were colocalized in ne

253 Immunofluorescence microscopy showed that ER beta protein was present in glycoprotein (GP) IIb(+)

254 ell lines, in which it was demonstrated that ER-beta mRNA was significantly up-regulated in the resis

255 Our data indicate that ER-beta is expressed at higher levels in Caco-2 cells an

256 The findings indicated that ER-beta-bearing inhibitory neurons project onto other GA

257 By Western blot analysis, we show that ER-beta protein is expressed in all cancer cell lines te

258 Evidence is also provided to show that ER-beta-catenin down-regulates cadherin protein levels.

259 We have recently shown that ER-beta mRNA is regulated by estradiol (E2) and that ant

260 after osmotic manipulation, suggesting that ER-beta expression was not driven by ligand availability

261 mediated ischemic protection suggesting that ER-beta plays a key role in mediating the beneficial eff

262 d the major groove of the DNA helix, but the ER beta DBD and hinge region failed to bend ERE-containi

263 The ER-beta agonist DPN did not mimic the effect of estradio

264 The ER-beta isoform is functionally similar to ER-alpha but

265 The ER-beta variant protein is predicted to lack part of the

266 ligand 16alpha-iodo-17beta-estradiol and the ER-beta selective ligand genistein failed to elicit ERK

267 Sequence analysis of the ER-beta variant PCR product revealed the absence of 139

268 reated ovariectomized C57BL/6J mice with the ER-beta selective agonist 2,2-bis(4-hydroxyphenyl)-propr

269 odies were made against a peptide within the ER-beta B domain.

270 This ER-beta deletion corresponds precisely to the entire exo

271 act on the OT system at two levels: through ER-beta, they regulate the production of OT in the hypot

272 Thus, ER beta may be a useful prognostic factor in patients wi

273 Thus, ER-beta behaves like a noncanonical type-I receptor, and

274 Thus, ER-beta exhibits extensive colocalization with a subclas

275 llowing sTNF inhibition in females is due to ER beta interference.

276 terestingly hPMC2 interacts more strongly to ER beta when compared with ER alpha.

277 enous gene, this element is nonresponsive to ER-beta but confers estrogen-dependent inhibition of tra

278 tence of additional relationships related to ER-beta and enzymes involved in hormone metabolism.

279 lly prepared aglycons bound significantly to ER-beta, except for 27-deoxyactein aglycon, which showed

280 P was shown to recognize in vitro translated ER beta, but not ER alpha, as well as a 60-kDa protein f

281 To test the specificity of DPN, we treated ER-beta-knockout mice with DPN.

282 f ER-beta that is coexpressed with wild-type ER-beta in the ER-alpha-negative, estrogen-independent b

283 nd E2 with lower affinity than the wild-type ER-beta protein.

284 estrogen action was signaled exclusively via ER-beta in normal human PrECs.

285 udy, we evaluated the effect of ER-alpha vs. ER-beta activation on ECM production, deposition, and un

286 s hormone, no studies have addressed whether ER beta can be similarly regulated.

287 R alpha, either alone or in combination with ER beta.

288 ressed more abundantly on EPCs compared with ER beta.

289 discernable activity with ER-alpha, but with ER-beta, E(2) was displaced with an IC(50) of 125 microM

290 or ER-alpha mRNA was very weak compared with ER-beta mRNA.

291 ol and testosterone were not correlated with ER-beta mRNA expression after osmotic manipulation, sugg

292 es and subjected to binding experiments with ER-beta.